Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis

Chia Chung Lee, Chun Liang Chen, Fei Lan Liu, Chung Yu Chiou, Tsung Chih Chen, Cheng Chi Wu, Wei Hsin Sun, Deh Ming Chang, Hsu Shan Huang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A series of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium derivatives was synthesized and evaluated for osteoclast inhibition using a TRAP-staining assay. Among them, two compounds, LCCY-13 and LCCY-15, dose-dependently suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. Moreover, the cytotoxicity assay on RAW264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds was not a result of their cytotoxicity. Further, the inhibitory activities of compounds LCCY-13 and LCCY-15 were further confirmed by including specific inhibition of NFATc1 expression levels in nuclei using an immunofluorescent analysis. In addition, LCCY-13 and LCCY-15 also significantly attenuated the bone resorption activity of osteoclasts according to a pit formation assay. Thus, a new class of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium compounds might be considered as an essential lead structure for the further development of anti-resorptive agents.

Original languageEnglish
Pages (from-to)342-355
Number of pages14
JournalArchiv der Pharmazie
Volume349
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Osteoclasts
Osteogenesis
Sodium
Bone Resorption
Sodium Compounds
Cytoplasmic and Nuclear Receptors
Staining and Labeling
Ligands
anthraquinone sulfonate

Keywords

  • Anthraquinone derivatives
  • Osteoclastogenesis
  • RANKL
  • TRAP-staining assay

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmaceutical Science

Cite this

Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis. / Lee, Chia Chung; Chen, Chun Liang; Liu, Fei Lan; Chiou, Chung Yu; Chen, Tsung Chih; Wu, Cheng Chi; Sun, Wei Hsin; Chang, Deh Ming; Huang, Hsu Shan.

In: Archiv der Pharmazie, Vol. 349, No. 5, 01.05.2016, p. 342-355.

Research output: Contribution to journalArticle

Lee, Chia Chung ; Chen, Chun Liang ; Liu, Fei Lan ; Chiou, Chung Yu ; Chen, Tsung Chih ; Wu, Cheng Chi ; Sun, Wei Hsin ; Chang, Deh Ming ; Huang, Hsu Shan. / Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis. In: Archiv der Pharmazie. 2016 ; Vol. 349, No. 5. pp. 342-355.
@article{2fd516e3540b4e3cba30fdb08fb97d09,
title = "Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis",
abstract = "A series of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium derivatives was synthesized and evaluated for osteoclast inhibition using a TRAP-staining assay. Among them, two compounds, LCCY-13 and LCCY-15, dose-dependently suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. Moreover, the cytotoxicity assay on RAW264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds was not a result of their cytotoxicity. Further, the inhibitory activities of compounds LCCY-13 and LCCY-15 were further confirmed by including specific inhibition of NFATc1 expression levels in nuclei using an immunofluorescent analysis. In addition, LCCY-13 and LCCY-15 also significantly attenuated the bone resorption activity of osteoclasts according to a pit formation assay. Thus, a new class of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium compounds might be considered as an essential lead structure for the further development of anti-resorptive agents.",
keywords = "Anthraquinone derivatives, Osteoclastogenesis, RANKL, TRAP-staining assay",
author = "Lee, {Chia Chung} and Chen, {Chun Liang} and Liu, {Fei Lan} and Chiou, {Chung Yu} and Chen, {Tsung Chih} and Wu, {Cheng Chi} and Sun, {Wei Hsin} and Chang, {Deh Ming} and Huang, {Hsu Shan}",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/ardp.201500475",
language = "English",
volume = "349",
pages = "342--355",
journal = "Archiv der Pharmazie",
issn = "0365-6233",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Development of 1-Amino-4-(phenylamino)anthraquinone-2-sulfonate Sodium Derivatives as a New Class of Inhibitors of RANKL-Induced Osteoclastogenesis

AU - Lee, Chia Chung

AU - Chen, Chun Liang

AU - Liu, Fei Lan

AU - Chiou, Chung Yu

AU - Chen, Tsung Chih

AU - Wu, Cheng Chi

AU - Sun, Wei Hsin

AU - Chang, Deh Ming

AU - Huang, Hsu Shan

PY - 2016/5/1

Y1 - 2016/5/1

N2 - A series of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium derivatives was synthesized and evaluated for osteoclast inhibition using a TRAP-staining assay. Among them, two compounds, LCCY-13 and LCCY-15, dose-dependently suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. Moreover, the cytotoxicity assay on RAW264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds was not a result of their cytotoxicity. Further, the inhibitory activities of compounds LCCY-13 and LCCY-15 were further confirmed by including specific inhibition of NFATc1 expression levels in nuclei using an immunofluorescent analysis. In addition, LCCY-13 and LCCY-15 also significantly attenuated the bone resorption activity of osteoclasts according to a pit formation assay. Thus, a new class of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium compounds might be considered as an essential lead structure for the further development of anti-resorptive agents.

AB - A series of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium derivatives was synthesized and evaluated for osteoclast inhibition using a TRAP-staining assay. Among them, two compounds, LCCY-13 and LCCY-15, dose-dependently suppressed receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation. Moreover, the cytotoxicity assay on RAW264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds was not a result of their cytotoxicity. Further, the inhibitory activities of compounds LCCY-13 and LCCY-15 were further confirmed by including specific inhibition of NFATc1 expression levels in nuclei using an immunofluorescent analysis. In addition, LCCY-13 and LCCY-15 also significantly attenuated the bone resorption activity of osteoclasts according to a pit formation assay. Thus, a new class of 1-amino-4-(phenylamino)anthraquinone-2-sulfonate sodium compounds might be considered as an essential lead structure for the further development of anti-resorptive agents.

KW - Anthraquinone derivatives

KW - Osteoclastogenesis

KW - RANKL

KW - TRAP-staining assay

UR - http://www.scopus.com/inward/record.url?scp=84963812619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963812619&partnerID=8YFLogxK

U2 - 10.1002/ardp.201500475

DO - 10.1002/ardp.201500475

M3 - Article

VL - 349

SP - 342

EP - 355

JO - Archiv der Pharmazie

JF - Archiv der Pharmazie

SN - 0365-6233

IS - 5

ER -